Catalyst Biosciences

Targacept, Catalyst Biosciences ink merger

Monday, March 9, 2015

Targacept, a biopharma company based in Winston-Salem, N.C., and Catalyst Biosciences, a privately held biopharma company based in South San Francisco, Calif., have agreed to merge. The combined entity, to be named Catalyst Biosciences, is expected to create a financially strong company to harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.

[Read More]

Catalyst Biosciences, Isu Abxis collaborate

Wednesday, October 9, 2013

Catalyst Biosciences,  a producer of novel biopharmaceutical products based on engineered human proteases, and Isu Abxis, a biologics manufacturing and development company based in Korea, have formed a strategic collaboration to develop Catalyst’s next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing and the completion of phase I clinical studies designed to establish proof-of-mechanism for the molecule in hemophilia B patients.

[Read More]